Skip to main content

Table 3 Grade 3-4 non-hemathologic toxicity in 51 patient receiving gemcitabine and docetaxel (GD)

From: Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone

G3-4 non-hemathologic toxicity Compliance Outcome GD cys
Allergic reaction (1st cycle) Stop docetaxel Resolved 2
Allergic reaction (1st cycle) Stop docetaxel Resolved 4
Allergic reaction (4th cycle) Stop docetaxel Resolved 5
Capillary leak syndrome Stop docetaxel Resolved 9
Diarrhea Delay/dose reduction Resolved 6
Febrile neutropenia Delay Resolved 7
Lung fibrosis None Resolved 5
Foot syndrome None Resolved 2
Stephen Johnson syndrome Stop docetaxel Off -treatment 1
  1. GD cys gemcitabine and docetaxel number of chemoteherapy cycles